The skirmish between Intarcia Therapeutics, Inc. and the US Food and Drug Administration’s Center for Drug Evaluation and Research over the company’s NDA for its exenatide implant ITCA 650 has extended into the planning of an advisory committee meeting. The panel is the firm’s chance to challenge CDER’s plan to refuse the application.
The company wants to narrow the scope of the meeting, which could occur this summer, and questions the inclusion of...
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Pink Sheet for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?